Corpus Intelligence IC Memo — PROVIDENCE VALDEZ MEDICAL CENTER 2026-04-26 09:35 UTC
IC Memo — PROVIDENCE VALDEZ MEDICAL CENTER
Investment Committee Memorandum | AK | 11 beds | Grade C | EBITDA uplift $1.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PROVIDENCE VALDEZ MEDICAL CENTER

CCN 021301 | VALDEZ-CORDOVA BOROUGH, AK | 11 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PROVIDENCE VALDEZ MEDICAL CENTER is a 11-bed suburban community hospital in VALDEZ-CORDOVA BOROUGH, AK with $20.0M in net patient revenue and a 8.4% operating margin. The hospital serves a payer mix of 37.3% Medicare, 16.5% Medicaid, and 46.2% commercial.

Thesis: Turnaround. Our ML models identify $1.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 8.4% to 15.7% (+736bps).

Net Revenue HCRIS$20.0M
Current EBITDA COMPUTED$1.7M
Operating Margin COMPUTED8.4%
Occupancy HCRIS21.4%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS78.8%
Distress Probability ML62.3%

2. Market Context & Competitive Position

24
AK Hospitals
-2.1%
State Median Margin
715
Comparable Hospitals

AK has 24 Medicare-certified hospitals with a median operating margin of -2.1%. The target's margin of 8.4% places it above the state median. Among 715 size-comparable peers (6-22 beds), the median margin is -9.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (6-22), prioritizing same-state peers. 715 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PROVIDENCE VALDEZ MEDICAL CENT (Target)AK11$20.0M8.4%
FRED HUTCHINSON CANCER CENTERWA20$1.17B-50.0%
WENATCHEE VALLEY HOSPITALWA11$277.5M-4.9%
PORTERVILLE DEVELOPMENTAL CENTCA17$193.6M-6.0%
NATIONAL JEWISH HEALTHCO13$150.4M-50.0%
NORTON SOUND REGIONAL HOSPITALAK18$148.7M-28.6%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
GREAT FALLS CLINIC MEDICAL CENMT20$132.1M21.0%
MARSHFIELD MEDICAL CENTER-MINOWI19$129.6M-12.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$421K+210bp18mo
Cost to Collect4.5%2.5%$401K+200bp12mo
Denial Rate Reduction12.0%6.5%$397K+198bp12mo
A/R Days Reduction5200.0%3800.0%$244K+122bp9mo
Clean Claim Rate88.0%96.0%$13K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$421K
Cost to Collect
$401K
Denial Rate Reduction
$397K
A/R Days Reduction
$244K
Clean Claim Rate
$13K
Total EBITDA Uplift$1.5M
Current EBITDA$1.7M
+ RCM Uplift+$1.5M
Pro Forma EBITDA$3.2M
Current Margin8.4%
Pro Forma Margin15.7%
WC Released (1x)$769K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.6M$25.8M10.01x58.5%
Base (11x exit)10.0x11.0x$2.6M$29.2M11.34x62.5%
Bull Case9.0x11.0x$2.3M$34.9M15.06x72.0%
Bull (12x exit)9.0x12.0x$2.3M$38.8M16.72x75.6%
Bear Case11.0x10.0x$2.8M$17.6M6.20x44.1%
Bear (11x exit)11.0x11.0x$2.8M$20.3M7.15x48.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 21.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 62.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 715 hospitals with 6-22 beds
  • Same-state prioritization (n=10)
  • Comp margins: P25=-24.1% / P50=-9.0% / P75=1.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.